87 related articles for article (PubMed ID: 22366655)
1. Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer.
Antoon JW; Beckman BS
Bioorg Med Chem Lett; 2012 Apr; 22(7):2624-8. PubMed ID: 22366655
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.
Antoon JW; Liu J; Gestaut MM; Burow ME; Beckman BS; Foroozesh M
J Med Chem; 2009 Sep; 52(18):5748-52. PubMed ID: 19694470
[TBL] [Abstract][Full Text] [Related]
3. Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides.
Liu J; Antoon JW; Ponnapakkam A; Beckman BS; Foroozesh M
Bioorg Med Chem; 2010 Jul; 18(14):5316-22. PubMed ID: 20639111
[TBL] [Abstract][Full Text] [Related]
4. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics.
Antoon JW; Liu J; Ponnapakkam AP; Gestaut MM; Foroozesh M; Beckman BS
Cancer Chemother Pharmacol; 2010 May; 65(6):1191-5. PubMed ID: 20155475
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and potent antileukemic activities of N-lactylsphingosine and N-lactyldihydrosphingosine.
Azuma H; Takao R; Shikata K; Niiro H; Tachibana T; Ogino K
J Med Chem; 2003 Jul; 46(16):3445-7. PubMed ID: 12877580
[TBL] [Abstract][Full Text] [Related]
6. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells.
Crawford KW; Bittman R; Chun J; Byun HS; Bowen WD
Cell Mol Biol (Noisy-le-grand); 2003 Nov; 49(7):1017-23. PubMed ID: 14682383
[TBL] [Abstract][Full Text] [Related]
7. Flexible, polymer-supported synthesis of sphingosine derivatives provides ceramides with enhanced biological activity.
El-Dahshan A; Al-Gharabli SI; Radetzki S; Al-Tel TH; Kumar P; Rademann J
Bioorg Med Chem; 2014 Oct; 22(19):5506-12. PubMed ID: 25172146
[TBL] [Abstract][Full Text] [Related]
8. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia.
Itoh M; Kitano T; Watanabe M; Kondo T; Yabu T; Taguchi Y; Iwai K; Tashima M; Uchiyama T; Okazaki T
Clin Cancer Res; 2003 Jan; 9(1):415-23. PubMed ID: 12538495
[TBL] [Abstract][Full Text] [Related]
9. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.
Struckhoff AP; Bittman R; Burow ME; Clejan S; Elliott S; Hammond T; Tang Y; Beckman BS
J Pharmacol Exp Ther; 2004 May; 309(2):523-32. PubMed ID: 14742741
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and growth inhibitory activity of chiral 5-hydroxy-2-N-acyl-(3E)-sphingenines: ceramides with an unusual sphingoid backbone.
Chun J; Byun HS; Arthur G; Bittman R
J Org Chem; 2003 Jan; 68(2):355-9. PubMed ID: 12530860
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 7-oxasphingosine and -ceramide analogues and their evaluation in a model for apoptosis.
Rajan R; Wallimann K; Vasella A; Pace D; Genazzani AA; Canonico PL; Condorelli F
Chem Biodivers; 2004 Nov; 1(11):1785-99. PubMed ID: 17191816
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of a ceramide analog containing a disulfide linkage.
Bittman R; Li Z; Samadder P; Arthur G
Cancer Lett; 2007 Jun; 251(1):53-8. PubMed ID: 17141948
[TBL] [Abstract][Full Text] [Related]
13. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells.
Kimura K; Markowski M; Edsall LC; Spiegel S; Gelmann EP
Cell Death Differ; 2003 Feb; 10(2):240-8. PubMed ID: 12700652
[TBL] [Abstract][Full Text] [Related]
14. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy.
Huwiler A; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2007 Aug; 63(2):150-9. PubMed ID: 17560117
[TBL] [Abstract][Full Text] [Related]
15. Ceramide synthesis and metabolism as a target for cancer therapy.
Reynolds CP; Maurer BJ; Kolesnick RN
Cancer Lett; 2004 Apr; 206(2):169-80. PubMed ID: 15013522
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
[TBL] [Abstract][Full Text] [Related]
17. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.
Rebbaa A; Chu F; Davis FB; Davis PJ; Mousa SA
Angiogenesis; 2008; 11(3):269-76. PubMed ID: 18386142
[TBL] [Abstract][Full Text] [Related]
18. Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30.
Wan JM; Sit WH; Louie JC
Int J Oncol; 2008 Mar; 32(3):689-99. PubMed ID: 18292947
[TBL] [Abstract][Full Text] [Related]
19. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.
Thuaud F; Bernard Y; Türkeri G; Dirr R; Aubert G; Cresteil T; Baguet A; Tomasetto C; Svitkin Y; Sonenberg N; Nebigil CG; Désaubry L
J Med Chem; 2009 Aug; 52(16):5176-87. PubMed ID: 19655762
[TBL] [Abstract][Full Text] [Related]
20. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
